rs10984447 — DBC1 DBC1 multiple sclerosis susceptibility variant

Intronic variant in DBC1 (DBCCR1/BRINP1) at 9q33.1 associated with multiple sclerosis susceptibility; the common A allele increases MS risk, while the minor G allele is protective

See your personal result for DBC1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

DBC1 9q33 — A Common Variant That Tips the Autoimmune Balance Toward MS

The DBC1 gene11 DBC1 gene
DBC1 (Deleted in Bladder Cancer 1), also known as DBCCR1 and BRINP1 (BMP/Retinoic Acid Inducible Neural Specific 1), sits at chromosome 9q33.1. The gene is expressed at highest levels in the brain and plays roles in DNA damage response, epigenetic regulation via SIRT1 inhibition, and cellular stress signaling sits at one of the genomic regions repeatedly flagged by multiple sclerosis genome-wide association studies. Its most common variant, rs10984447, illustrates an unusual feature of MS genetics: the reference (major) allele is the susceptibility allele, and rarer protective variant carriers are the genetic minority.

Multiple sclerosis is a chronic neuroinflammatory disease22 chronic neuroinflammatory disease
MS affects approximately 2.8 million people worldwide; autoimmune CD4+ T cells drive demyelination of the central nervous system, leading to relapsing or progressive neurological disability caused by misdirected immune attacks on central nervous system myelin. Genetic predisposition accounts for roughly 20–30% of MS risk, with the HLA-DRB1*15:01 allele as the dominant single factor (OR ≈ 3.1). The remaining non-HLA genetic risk is distributed across over 100 loci, each contributing modest effect sizes — rs10984447 at 9q33 is among these smaller-effect contributors.

The Mechanism

DBC1 protein is a nuclear scaffold that physically binds and inhibits SIRT133 SIRT1
SIRT1 is an NAD+-dependent deacetylase that regulates inflammation, DNA repair, and immune cell differentiation; DBC1-SIRT1 interaction modulates NF-κB activity and T-cell activation thresholds, keeping the deacetylase in check under basal conditions. Cellular stress signals (genotoxic damage, oxidative stress) disrupt the DBC1–SIRT1 complex and activate SIRT1-dependent gene programs involved in DNA damage response and apoptosis. Because SIRT1 is a central regulator of T-cell differentiation — suppressing Th17 fate while promoting Treg stability — subtle changes in DBC1 expression or function in immune cells could shift the balance toward pro-inflammatory T-cell programs associated with autoimmune pathology.

rs10984447 is an intronic variant located within a CpG island that is a known hypermethylation target in cancer. Whether this specific variant alters splicing, expression, or epigenetic marking at the DBC1 locus in immune cells has not been directly demonstrated — the MS association is a genome-wide tagging signal, and the precise functional mechanism remains to be established. The variant may mark a regulatory haplotype rather than having a direct intrinsic effect.

The Evidence

The primary MS association comes from the International Multiple Sclerosis Genetics Consortium 2011 GWAS44 International Multiple Sclerosis Genetics Consortium 2011 GWAS
Sawcer et al. analysed 9,772 MS cases and 17,376 controls of European ancestry plus an independent replication cohort, identifying multiple novel loci outside the HLA region with effects in the OR 1.1–1.3 range. rs10984447 at the DBC1 locus emerged with OR ≈ 1.17 (p = 8 × 10⁻⁶ at genome-wide suggestive threshold, but below the conventional 5 × 10⁻⁸ genome-wide significance threshold).

Replication in different ancestry groups adds some robustness. Al Jumah et al. (2012)55 Al Jumah et al. (2012)
342 subjects: 99 sporadic MS, 22 familial MS, 89 related controls, 132 independent controls in a Saudi Arabian cohort — genetically homogenous population reduces confounding found a substantially larger effect size in familial MS cases vs independent controls (OR 13.63, 95% CI 1.54–120.83). The wide confidence interval reflects the small familial MS group (n=22), but replication in a non-European population with independent methodology supports the variant's genuine relevance.

The broader 9q33 MS signal sits within the context of Beecham et al. (2013)66 Beecham et al. (2013)
ImmunoChip analysis of immune-related loci in over 80,000 individuals of European ancestry; confirmed 110 non-HLA MS susceptibility variants, establishing the polygenic landscape within which this locus operates. The modest individual effect (OR 1.17) is consistent with the general architecture of non-HLA MS genetics — many loci, each contributing small increments of risk that compound across the genome.

The evidence level is rated moderate: the 2011 GWAS signals a locus-level association but rs10984447 did not reach genome-wide significance independently, and the causal variant at 9q33 has not been fine-mapped. The Saudi replication supports the signal without resolving the mechanistic question.

Practical Actions

For those carrying one or two A alleles: the individual effect of this variant is small (OR 1.17 per allele from the European cohort). Carrying AA does not mean MS is likely — lifetime MS incidence is approximately 0.3% in the general population, and a 17% per-allele increase brings this to a still-small absolute risk increment. Risk is meaningfully elevated only when this variant combines with high-impact MS risk alleles (notably HLA-DRB1*15:01, IL7R rs6897932, and PTPN22 rs2476601).

The actionable focus is monitoring for early MS symptoms — particularly episodes of optic neuritis, limb weakness, or sensory disturbances — and ensuring vitamin D sufficiency, which has the strongest environmental evidence for reducing MS incidence in genetically susceptible individuals.

Interactions

The DBC1 locus contributes to MS risk additively with other established non-HLA MS susceptibility variants. In particular, IL7R rs6897932 (CC genotype) and PTPN22 rs2476601 (AA genotype) operate through distinct immune cell mechanisms (IL-7 signaling and T-cell activation thresholds, respectively) and compound with 9q33 variants to further elevate polygenic risk. Individuals carrying risk alleles at multiple MS loci have substantially greater susceptibility than the individual SNP odds ratios would predict in isolation.

Genotype Interpretations

What each possible genotype means for this variant.

GG Protective Variant Normal

Two copies of the rare protective G allele — lowest MS susceptibility from this locus

You carry two copies of the G allele at rs10984447, the minor allele at this locus (approximately 6% of people globally). The G allele is the protective variant — it is associated with reduced MS susceptibility compared to the common A allele. This genotype represents the lowest MS risk contribution from the DBC1 9q33 locus. Roughly 5-6% of people of European descent and fewer in East Asian and African populations share this genotype.

AG Partial Risk Intermediate

One risk allele — modestly elevated MS susceptibility from this locus

The AG genotype at rs10984447 represents one dose of the DBC1 MS risk haplotype. In the large IMSGC 2011 GWAS (9,772 MS cases, 17,376 controls), each A allele conferred roughly a 17% increase in MS odds. This effect is additive, so AG heterozygotes sit between the GG (lowest) and AA (highest) susceptibility categories for this locus.

The DBC1 gene's role in SIRT1 inhibition and DNA damage response may connect to immune regulation, but the mechanism by which this intronic variant influences MS risk has not been experimentally established. The 9q33 signal is one of over 100 non-HLA MS susceptibility loci, each with individually modest effects that sum to a meaningful polygenic score. Whether rs10984447 acts directly or tags a nearby causal regulatory variant is not yet resolved.

Your overall MS genetic risk depends heavily on HLA alleles (especially DRB1*15:01) and other high-effect loci (IL7R rs6897932, PTPN22 rs2476601) — this locus is a secondary contributor.

AA Common Risk Allele High Risk

Two copies of the common risk A allele — the highest-risk genotype at this locus for MS

The AA genotype is counterintuitive in the context of genetic risk: here, the most common genotype is also the highest-risk configuration. The protective G allele is the minor variant (~23% globally), meaning only about 6% of people carry the fully protective GG genotype. The majority of the population carries at least one A allele.

The absolute MS risk increment from this genotype alone remains small. Global MS prevalence is approximately 0.3% in populations of European descent; even with an odds ratio of roughly 1.17 per allele (applied additively), the absolute lifetime risk increase from AA homozygosity is small in isolation. The clinical significance of this genotype depends critically on co-occurring MS risk variants — particularly HLA-DRB1*15:01, which alone triples MS risk and which, combined with non-HLA susceptibility alleles like rs10984447, compounds polygenic risk substantially.

From a mechanistic standpoint, DBC1 is expressed at high levels in the brain and regulates SIRT1, an enzyme that controls inflammatory gene programs in immune cells and supports Treg function. Whether the DBC1 9q33 haplotype tagged by the A allele at rs10984447 alters immune cell DBC1 expression or function has not been demonstrated, making this a locus-level association rather than a mechanistically resolved risk signal.